Ascendis Pharma A/S (BVMF:A1SN34)
Brazil
· Delayed Price · Currency is BRL 76.05
-2.52 (-3.21%)
At close: Mar 24, 2026
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
3.92M BRL
Profits / Employee
-1.24M BRL
Market Cap
69.70B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Raia Drogasil | 73,895 |
| Hypera | 10,564 |
| Fleury | 28,000 |
| Diagnósticos da América | 26,255 |
| Empreendimentos Pague Menos | 28,207 |
| Blau Farmacêutica | 1,900 |
| Dimed S.A. Distribuidora de Medicamentos | 11,282 |
| Ouro Fino Saúde Animal Participações | 1,086 |
Ascendis Pharma News
- 7 days ago - Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 - GlobeNewsWire
- 8 days ago - Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq - GlobeNewsWire
- 20 days ago - Ascendis Pharma to List Ordinary Shares Directly on Nasdaq - GlobeNewsWire
- 20 days ago - New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia - GlobeNewsWire
- 22 days ago - Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States - GlobeNewsWire
- 6 weeks ago - New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 - GlobeNewsWire
- 6 weeks ago - New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026 - GlobeNewsWire
- 2 months ago - Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire